|Clinical Relevance:||Dabigatran etexilate is a direct thrombin inhibitor which is now clinically used for the prophylaxis and treatment of the thrombosis and related cardiovascular disease. It has been cleared for use without any laboratory monitoring based on its safe pharmokinetic and pharmodynamic profile and short half-life. In certain circumstances measurement of the plasma concentration may aid medical decisions(e.g emergency surgery/severe bleeding).|
A level of 200-400ng/mL at 2-4 hours post-dose reflects therapeutic anticoagulation.
A level 50-150ng/mL is considered a through level. A level of <30ng/mL should reflect negligible anticoagulant effect.
|Min. Volume:||The volume of blood in coagulation samples must lie within the volume range as indicated by the size of the black fill arrow present on tubes. Volumes above or below the arrow will result in sample rejection to ensure validity of results.|
|Turnaround Time:||4 hours|
|Age of Sample:||Samples will be rejected if received more than 2 hours post venepuncture.|
|Analysing Laboratory:||Coagulation (JCUH)|